The Acute Coronary Syndrome Risk in Medically Managed Subjects with Type 2 Diabetes Mellitus : Is the ASCVD Risk Score Failing Here?

Ameya Joshi; Harminder  Singh; Sanjay Kalra

doi:10.15605/jafes.039.01.15

Authors

Ameya Joshi Bhaktivedanta Hospital and Research Institute
Harminder Singh Bhaktivedanta Hospital and Research Institute.
Sanjay Kalra Bharti Hospital https://orcid.org/0000-0003-1308-121X

DOI:

https://doi.org/10.15605/jafes.039.01.15

Keywords:

ASCVD, Acute coronary syndrome, family history

Abstract

Objectives. Type 2 Diabetics have elevated risk for acute coronary syndrome (ACS). The current management algorithm focuses on atherosclerotic cardiovascular (ASCVD) risk score to stratify this risk. However, in medically managed subjects, this algorithm may not be accurate. This study compares the ASCVD risk score in an Indian population with T2DM under medical supervision and the actual incidence of ACS. It also compared the ASCVD risk scores in cases with T2DM who developed ACS to controls and tried to estimate whether the ASCVD risk score is different in the two subsets, evaluating the utility of the ASCVD risk score in predicting ACS.

Methodology. This is an electronic medical record (EMR) based case-control study. Only records of subjects with T2DM where details of age, sex, body mass index, blood pressure, duration of diabetes, family history of ACS, lipid profile, renal and liver function tests were included. The incidence of ACS was calculated in the selected records, and the records of subjects with ACS were compared with age and sex-matched subjects without ACS. Data are summarized as median and interquartile range (IQR). Wilcoxon rank-sum test was used for checking differences in continuous variables and Pearson’s Chi-squared test for categorical data. Univariate and multivariate logistic regression analyses were used to check the effect of ASCVD scores and other variables on the occurrence of ACS.

Statistical data analyses were performed using JASP, version 0.16.4 (JASP Team [2022]) for MS Windows.

Results. Of the 1226 EMRs included in the analysis, 207 had ACS. The actual incidence of ACS was 16.85% in 6 years, higher than the mean predicted 10-year incidence of 14.56 percent (p <0.05). The cases were age and sex-matched with controls and the ASCVD incidence was estimated in the two groups. The mean ASCVD score in the cases was 14.565 ± 8.709 (Min: 1.5, Max: 38.3) and controls 13.114 ± 8.247 (Min: 1.4, Max: 45).

The chance of development of ACS increases with elevated systolic blood pressure (per mmHg rise OR: 1.04, 95% CI: 1.03, 1.06; p <0.001), positive family history (OR: 5.70, 95% CI: 3.41, 9.77; p <0.001), statin use (OR: 2.26, 95% CI: 1.46, 3.52; p <0.001), and longer duration of diabetes (for every year increase OR: 1.19, 95% CI: 1.13, 1.25; p <0.001)

Conclusion. The ASCVD risk score underestimates the ACS risk in subjects with T2DM under medical supervision and may not differ in those who developed and did not develop ACS. We also conclude that factors like a negative family history (30% less risk), longer duration of diabetes, and higher SBP are relevant in those who developed ACS.

Downloads

Download data is not yet available.

Author Biographies

Ameya Joshi, Bhaktivedanta Hospital and Research Institute

Department of Endocrinology, Bhaktivedanta Hospital and Research Institute, Maharashtra, India

Harminder Singh, Bhaktivedanta Hospital and Research Institute.

Department of Cardiology, Bhaktivedanta Hospital and Research Institute, Maharashtra, India

Sanjay Kalra, Bharti Hospital

Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India

References

Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF Diabetes Atlas, 10th ed. Brussels: International Diabetes Federation; 2021. https://diabetesatlas.org/resources/?gclid=Cj0KCQiAwvKtBhDrARIsAJj-kTjoXjEinHxQWaGxa_gG9Xpfk1etSyh0wsKDISykQpBXbl1nh0HI2PoaAsrQEALw_wcB.

American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–28. https://pubmed.ncbi.nlm.nih.gov/29567642. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911784. https://doi.org/10.2337/dci18-0007.

American Diabetes Association Professional Practice Committee; 10. Cardiovascular disease and risk management: Standards of medical care in diabetes - 2022. Diabetes Care. 2022;45(Suppl 1): S144-74.

DeFilippis AP, Young R, McEvoy JW, et al. Risk score overestimation: The impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38(8):598–608. https://pubmed.ncbi.nlm.nih.gov/27436865. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837662. https://doi.org/10.1093/eurheartj/ehw301.

Sreeniwas Kumar A, Sinha N. Cardiovascular disease in India: A 360 degree overview. Med J Armed Forces India. 2020;76(1):1-3. https://pubmed.ncbi.nlm.nih.gov/32020960. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994761. https://doi.org/10.1016/j.mjafi.2019.12.005.

Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol. 2010;35(2):72–115. https://pubmed.ncbi.nlm.nih.gov/20109979. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864143. https://doi.org/10.1016/j.cpcardiol.2009.10.002.

American College of Cardiology. ASCVD risk estimator plus. http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/. Accessed February 16, 2023.

Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, et al. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol. 2018;71(22):2497-2506. https://pubmed.ncbi.nlm.nih.gov/29852973. https://doi.org/10.1016/j.jacc.2018.01.085.

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168–3209. https://pubmed.ncbi.nlm.nih.gov/30423391. https://doi/org/10.1016/j.jacc.2018.11.002.

Garg N, Muduli SK, Kapoor A, et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J. 2017;69(4):458-63. https://pubmed.ncbi.nlm.nih.gov/28822511. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560874. https://doi.org/10.1016/j.ihj.2017.01.015.

Wahrenberg A, Magnusson PK, Discacciati A, et al. Family history of coronary artery disease is associated with acute coronary syndrome in 28,188 chest pain patients. Eur Heart J Acute Cardiovasc Care. 2020;9(7):741-7. https://pubmed.ncbi.nlm.nih.gov/31124704. https://doi.org/10.1177/2048872619853521.

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-86. https://pubmed.ncbi.nlm.nih.gov/36148880. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008140. https://doi.org/10.2337/dci22-0034.

Malachias MVB, Wijkman MO, Bertoluci MC. NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes. Diabetol Metab Syndr. 2022;14(1):64. https://pubmed.ncbi.nlm.nih.gov/35501909. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063067. https://doi.org/10.1186/s13098-022-00837-6.

Sow MA, Magne J, Salle L, Nobecourt E, Preux PM, Aboyans V. Prevalence, determinants and prognostic value of high coronary artery calcium score in asymptomatic patients with diabetes: A systematic review and meta-analysis. J. Diabetes Complicat. 2022;36(8):108237. https://pubmed.ncbi.nlm.nih.gov/35773171. https://doi.org/10.1016/j.jdiacomp.2022.108237.